Literature DB >> 8573520

Karyotyping of fluconazole-resistant yeasts with phenotype reported as Candida krusei or Candida inconspicua.

S M Essayag1, G G Baily, D W Denning, J P Burnie.   

Abstract

The yeasts Candida krusei and Candida inconspicua have similar phenotypes, which may make discrimination of these organisms difficult. In this study we determined the karyotypes of 51 isolates of these two yeast species by contour-clamped homogeneous electric field electrophoresis. We found that the 43 isolates that had the C. krusei phenotype had three karyotype-specific characteristics. These isolates produced either two or three bands between 2,000 and 3,000 kb and no band between 1,300 and 2,000 kb, and there was either a single bright band at 1,300 or 1,200 kb or two separate bands at 1,300, 1,200, or 1,100 kb. Using this technique, we were able to distinguish 27 different C. krusei types on the basis of band variations. The seven isolates identified as C. inconspicua on the basis of phenotype differed in that they produced at least one band between 1,300 and 2,000 kb. These isolates produced six to nine bands, in contrast to C. krusei strains, which produced three to six bands. The MIC of fluconazole for all of the isolates was at least 12.5 mg/liter, as determined by a broth dilution method.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8573520     DOI: 10.1099/00207713-46-1-35

Source DB:  PubMed          Journal:  Int J Syst Bacteriol        ISSN: 0020-7713


  7 in total

Review 1.  The ins and outs of DNA fingerprinting the infectious fungi.

Authors:  D R Soll
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

2.  Species differentiation by internally transcribed spacer PCR and HhaI digestion of fluconazole-resistant Candida krusei, Candida inconspicua, and Candida norvegensis strains.

Authors:  S Nho; M J Anderson; C B Moore; D W Denning
Journal:  J Clin Microbiol       Date:  1997-04       Impact factor: 5.948

3.  Restriction enzyme analysis of ribosomal DNA shows that Candida inconspicua clinical isolates can be misidentified as Candida norvegensis with traditional diagnostic procedures.

Authors:  L Majoros; G Kardos; A Belák; A Maráz; L Asztalos; E Csánky; Z Barta; B Szabó
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

4.  Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90.

Authors:  Ruth C Matthews; Gordon Rigg; Samantha Hodgetts; Tracey Carter; Caroline Chapman; Carl Gregory; Chris Illidge; James Burnie
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

5.  In vitro susceptibility of 137 Candida sp. isolates from HIV positive patients to several antifungal drugs.

Authors:  S Magaldi; S Mata; C Hartung; G Verde; L Deibis; Y Roldán; C Marcano
Journal:  Mycopathologia       Date:  2001       Impact factor: 3.785

6.  Genetic relationships between Candida albicans strains isolated from dental plaque, trachea, and bronchoalveolar lavage fluid from mechanically ventilated intensive care unit patients.

Authors:  Seok-Mo Heo; Robert S Sung; Frank A Scannapieco; Elaine M Haase
Journal:  J Oral Microbiol       Date:  2011-06-20       Impact factor: 5.474

7.  Whole Genome Sequence of the Heterozygous Clinical Isolate Candida krusei 81-B-5.

Authors:  Christina A Cuomo; Terrance Shea; Bo Yang; Reeta Rao; Anja Forche
Journal:  G3 (Bethesda)       Date:  2017-09-07       Impact factor: 3.154

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.